Trial Profile
Investigation of an efficacy of eplerenone combined therapy for hypertensive patients with chronic kidney disease that enough hypotensive effect are not obtained with an angiotensin receptor blocker
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2017
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary) ; Hydrochlorothiazide; Trichlormethiazide
- Indications Hypertension; Renal failure
- Focus Therapeutic Use
- Acronyms OWASE
- 28 Aug 2017 Primary endpoint (Mean percent change in UACR) has not been met, according to the results published in the Journal of Clinical Hypertension (Greenwich).
- 28 Aug 2017 Results published in the Journal of Clinical Hypertension (Greenwich)
- 29 Sep 2016 Results of subanalysis (n=68) presented at the 26th Scientific Meeting of the International Society of Hypertension